<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03281265</url>
  </required_header>
  <id_info>
    <org_study_id>002</org_study_id>
    <nct_id>NCT03281265</nct_id>
  </id_info>
  <brief_title>A Retrospective Multicenter Study of HBV-related Pre-acute-on-chronic Liver Failure in China</brief_title>
  <official_title>A Retrospective Multicenter Study of HBV-related Pre-acute-on-chronic Liver Failure in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanfang Hospital of Southern Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The definition and diagnostic criteria of Acute-on-chronic liver failure (ACLF) has been well&#xD;
      established by EASL CANONIC study. However, patients with high risk to develop ACLF has not&#xD;
      been determined, yet. The aim of current study is to establish a preliminary pre-ACLF&#xD;
      definition, and to demonstrate the corresponding risk factors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2012</start_date>
  <completion_date type="Actual">February 28, 2017</completion_date>
  <primary_completion_date type="Actual">February 28, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>28-day ACLF progression</measure>
    <time_frame>28-day</time_frame>
    <description>progressed to EASL defined ACLF</description>
  </primary_outcome>
  <primary_outcome>
    <measure>28-day mortality</measure>
    <time_frame>28-day</time_frame>
    <description>death within 28-day</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>90-day mortality</measure>
    <time_frame>90-day</time_frame>
    <description>death within 90-day</description>
  </secondary_outcome>
  <enrollment type="Actual">1178</enrollment>
  <condition>Liver Failure, Acute on Chronic</condition>
  <condition>Liver Injury</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>standard treatment</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with HBV-related compensated liver disease and acute liver injury or&#xD;
        decompensation.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Chronic hepatitis B virus infection;&#xD;
&#xD;
          2. Any of the followings: Alanine aminotransferase (ALT)≥3 upper limit of laboratory&#xD;
             reference (ULN); Aspartate aminotransferase (AST)≥3 ULN; Serum bilirubin≥2 ULN; Acute&#xD;
             decompensation (ascites, hepatic encephalopathy, variceal hemorrhage and/or bacterial&#xD;
             infections)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous decompensation;&#xD;
&#xD;
          2. those who had hepatocellular carcinoma or other types of malignancies;&#xD;
&#xD;
          3. those who combined with severe chronic extra-hepatic disease;&#xD;
&#xD;
          4. pregnant;&#xD;
&#xD;
          5. received liver transplantation or kidney transplantation before or after admission;&#xD;
&#xD;
          6. readmission;&#xD;
&#xD;
          7. death within 24 hours.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
  </eligibility>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>September 11, 2017</study_first_submitted>
  <study_first_submitted_qc>September 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2017</study_first_posted>
  <last_update_submitted>January 19, 2018</last_update_submitted>
  <last_update_submitted_qc>January 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pre-acute-on-chronic liver failure</keyword>
  <keyword>hepatitis B</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>Hepatic Insufficiency</mesh_term>
    <mesh_term>End Stage Liver Disease</mesh_term>
    <mesh_term>Acute-On-Chronic Liver Failure</mesh_term>
    <mesh_term>Liver Failure, Acute</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

